Lessons from Epidemiology: The Burden of Liver Disease
暂无分享,去创建一个
[1] T. Therneau,et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States , 2013, Hepatology.
[2] D. Couper,et al. Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide. , 2016, Journal of hepatology.
[3] H. Sørensen,et al. Risk for Hepatocellular Carcinoma in Patients With Alcoholic Cirrhosis , 2012, Annals of Internal Medicine.
[4] Alan Brennan,et al. Effects of minimum unit pricing for alcohol on different income and socioeconomic groups: a modelling study , 2014, The Lancet.
[5] J. Sung,et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. , 1987, JAMA.
[6] A. Schoepfer,et al. Therapy: Positioning of dilation in eosinophilic oesophagitis , 2016, Nature Reviews Gastroenterology &Hepatology.
[7] R. Peto,et al. Alcohol and mortality in Russia: prospective observational study of 151 000 adults , 2014, The Lancet.
[8] J. Ioannidis,et al. Is widespread screening for hepatitis C justified? , 2015, BMJ : British Medical Journal.
[9] Alan Brennan,et al. Potential benefits of minimum unit pricing for alcohol versus a ban on below cost selling in England 2014: modelling study , 2014, BMJ : British Medical Journal.
[10] D. Randall,et al. The increasing mortality burden of liver disease among opioid-dependent people: cohort study. , 2011, Addiction.
[11] A. Treno,et al. The relationship between minimum alcohol prices, outlet densities and alcohol-attributable deaths in British Columbia, 2002-09. , 2013, Addiction.
[12] Bernadette A. Thomas,et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.
[13] Chien-Jen Chen,et al. Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. , 2016, Gastroenterology.
[14] B. Neuschwander‐Tetri,et al. End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease. , 2016, Gastroenterology.
[15] E. Bjornsson,et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. , 2013, Gastroenterology.
[16] E. Bjornsson,et al. Alcohol consumption and liver cirrhosis mortality after lifting ban on beer sales in country with state alcohol monopoly. , 2015, European journal of public health.
[17] A. Nemtsov. Alcohol-related human losses in Russia in the 1980s and 1990s. , 2002, Addiction.
[18] D. Nickle,et al. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. , 2016, Annals of internal medicine.
[19] P. Maisonneuve,et al. Sustained virological response to treatment in patients with chronic hepatitis C. , 2013, Journal of the American Medical Association (JAMA).
[20] K. Kielland,et al. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. , 2013, Journal of hepatology.
[21] Nobhojit Roy,et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition , 2015, The Lancet.
[22] P. Gruenewald,et al. Alcohol outlet densities and alcohol price: the British Columbia experiment in the partial privatization of alcohol sales off-premise. , 2013, Alcoholism, clinical and experimental research.
[23] N. Sheron. Alcohol and liver disease in Europe--Simple measures have the potential to prevent tens of thousands of premature deaths. , 2016, Journal of hepatology.
[24] Reza Assadi,et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.
[25] E. Bjornsson,et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.
[26] P. Vickerman,et al. Cost‐effectiveness of hepatitis C virus antiviral treatment for injection drug user populations , 2012, Hepatology.
[27] L. Henry,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.
[28] H. Janssen,et al. Sustained virological response to treatment in patients with chronic hepatitis C--reply. , 2013, JAMA.
[29] A. Mangia,et al. Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study , 2007, Hepatology.
[30] Mats Fredrikson,et al. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.
[31] M. Hellard,et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals , 2013, Hepatology.
[32] A. Sanyal. Reply: To PMID 24818764. , 2015, Gastroenterology.
[33] A. V. D. Meer,et al. Faculty Opinions recommendation of Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. , 2016 .
[34] J. Hoofnagle,et al. From non-A, non-B hepatitis to hepatitis C virus cure. , 2015, Journal of hepatology.